Background In a previous systematic review and meta-analysis, we assessed the efficacy
and safety of nonvitamin-K antagonist oral anticoagulants versus warfarin in patients with …

Background and Purpose—To assess whether the combined analysis of all phase III trials of
nonvitamin-K-antagonist (non-VKA) oral anticoagulants in patients with atrial fibrillation and …

Abstract Background and Objectives Atrial fibrillation (AF) and the associated risk of stroke
are emerging epidemics throughout the world. Suboptimal use of oral anticoagulants for …

The new oral anticoagulants/non-vitamin K antagonists oral anticoagulants (NOACs) have
recently reached the market and less is known about their safety in comparison to their …

Background Novel oral anticoagulants are approved in several indications: rivaroxaban,
apixaban, and dabigatran for the prevention of venous thromboembolism after elective hip …

Warfarin's time-in-therapeutic range (TTR) is highly variable among patients with
nonvalvular atrial fibrillation (NVAF). The objective of this study was to estimate the impact of …

Thrombosis is one of the major causes of morbidity and mortality in a wide range of vessels
diseases. Due to the high prevalence of thromboembolic disorders investigations are being …

Atrial fibrillation (AF) is a leading cause of stroke. Oral anticoagulant (OAC) therapy can
significantly reduce the risk of stroke in patients with AF, but underuse of OACs for stroke …

We did a cost-utility analysis for the new oral anticoagulants (NOACs) in the German
population based on the quality-adjusted life years (QALY), total costs, and incremental cost …

Background Stroke represents a major complication of atrial fibrillation (AF). The current
anticoagulation options for stroke prevention increase hemorrhage risk. The objective of the …